Sustainable and effective lipid-lowering management: prevention strategies from the BRING-UP prevention study
Open Access
- 8 February 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (4) , 632-643
Abstract
Aims: Adherence to guideline recommendations for secondary prevention appears to be inadequate, even in cardiology centres. To narrow the gap between guideline recommendations and what is implemented in clinical practice, we designed the BRING-UP Prevention project. Methods and results: BRING-UP Prevention is a nationwide, observational, prospective, multicenter study enrolling patients with a prior atherothrombotic event. The study consists of two 3-month enrolment phases followed by a 6-month follow-up, with each phase preceded by an educational intervention. Data presented here mainly focus on the percentage of patients at goal for LDL-cholesterol (LDL-C) (<55 mg/dL) at the 6-month follow-up in the recently completed first enrolment phase. Secondary endpoints are blood pressure, glycaemic and weight control, and smoking cessation. Over 3 months, 189 cardiology centres recruited 4790 patients. Follow-up data at 6 months were available for 4643 patients (97%) and LDL-C was available for 4334 of them. The rate of patients with LDL-C < 55 mg/dL increased from 33% to 58.1%, with absolute and relative increases of 25.1% and 76.1%, respectively. At 6 months, 94.9% of patients were prescribed statins. Atorvastatin and rosuvastatin were the most prescribed statins, mostly at high doses. Ezetimibe was prescribed in 84% of cases. PCSK9i monoclonal antibodies and inclisiran were prescribed in 8.3% of patients. Conclusion: BRING-UP prevention achieved its primary goal to increase the percentage of patients at the LDL-C goal, demonstrating that, in many patients, this goal can be achieved by increasing the use of low-cost therapies. ClinicalTrial.gov: NCT06275113Keywords
Funding Information
- Heart Care Foundation of India
- ANMCO
- Amgen
- Daiichi Sankyo Italia
- Novartis Italia
This publication has 23 references indexed in Scilit:
- LDL-cholesterol levels and lipid lowering therapy in secondary prevention. Baseline data from the BRING-UP prospective registryInternational Journal of Cardiology, 2025
- 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertensionEuropean Journal of Internal Medicine, 2024
- BLITZ‐HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelinesEuropean Journal of Heart Failure, 2022
- Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019JACC, 2020
- Behavioral Counseling to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk FactorsJAMA, 2020
- Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER studyAtherosclerosis, 2020
- Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countriesAtherosclerosis, 2019
- Exploring the Barriers to and Facilitators of Using Evidence-Based Drugs in the Secondary Prevention of Cardiovascular Diseases: Findings From a Multistakeholder, Qualitative AnalysisGlobal Heart, 2018
- Use of lipid lowering drugs in patients at very high risk of cardiovascular events: An analysis on nearly 3,000,000 Italian subjects of the ARNO ObservatoryInternational Journal of Cardiology, 2017
- Programme to Improve the Use of Beta-Blockers for Heart Failure in the Elderly and in those with Severe Symptoms: Results of the BRING-UP 2 StudyEuropean Journal of Heart Failure, 2006